UPDATE 2-AbbVie prices new rheumatoid arthritis drug at $59,000/yr
August 16, 2019 at 14:19 PM EDT
AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition.